Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of CKD-380 vs D308 in Healthy Males
NCT03601910Phase 1Unknown
- Sponsor
- Chong Kun Dang Holdings
- Start
- Jul 2018
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dapagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Curve to the last measurable concentration at 48 hours and Maximum Plasma Concentration at 48 hours. Status: unknown.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03601910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03601910.